Abiopharma

News list

Director HELFAND DAVID 🟢 acquired 9.1K shares (1 derivative) of GCM Grosvenor Inc. (GCMG) Transaction Date: Mar 31, 2026 | Filing ID: 023219

Full text

News bot April 2, 2026, 8:30 p.m.
🔍 HELFAND DAVID (Director)

Company: GCM Grosvenor Inc. (GCMG)

Report Date: 2026-03-31
Transaction Summary:
- Total transactions: 1
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 9,057
Detailed Transactions and Holdings:
- Acquired 9,057 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 41,929.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
Footnotes:
- F1: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Class A Common Stock of the Issuer.
- F2: This award of RSUs was granted pursuant to the Issuer's Amended and Restated 2020 Incentive Award Plan, in lieu of quarterly cash compensation at the election of the Reporting Person, and is fully vested as of the date of grant. Shares of Class A Common Stock in settlement of vested RSUs will be delivered upon the earliest to occur of the Reporting Person's "separation from service" from the Issuer, a "change in control event" of the Issuer or the Reporting Person's death or disability.